Next Article in Journal
NIR Rapid Assessments of Blumea balsamifera (Ai-na-xiang) in China
Next Article in Special Issue
Hop Phytochemicals and Their Potential Role in Metabolic Syndrome Prevention and Therapy
Previous Article in Journal
Caustic Ingestion in the Elderly: Influence of Age on Clinical Outcome
Previous Article in Special Issue
Long Term Osmotic Mini Pump Treatment with Alpha-MSH Improves Myocardial Function in Zucker Diabetic Fatty Rats
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Molecules 2017, 22(10), 1725;

Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model

Olygose, Rue les Rives de l’Oise, Venette 60200, France
Biomeostasis, ActiParc I - Bat.6 Traverse de la Penne, La Penne-sur-Huveaune 13821, France
Author to whom correspondence should be addressed.
Received: 31 August 2017 / Revised: 10 October 2017 / Accepted: 11 October 2017 / Published: 14 October 2017
(This article belongs to the Special Issue Bioactive Compounds for Metabolic Syndrome and Type 2 Diabetes)
Full-Text   |   PDF [1733 KB, uploaded 14 October 2017]   |  


Non-Alcoholic Fatty Liver Disease (NAFLD) is the major liver disease worldwide and is linked to the development of metabolic syndrome and obesity. As alpha-galacto-oligosaccharides (α-GOS) from legumes have been shown to reduce body weight and hyperphagia in overweight adults, it was hypothesized that they would exert benefits on the development of metabolic syndrome and associated NAFLD in a rodent model. C57Bl/6J mice were fed a high-fat diet until they developed metabolic syndrome and were then orally treated either with α-GOS at a physiological dose (2.2 g/kg BW/d) or the vehicle over 7 weeks. α-GOS induced a reduction in food intake, but without affecting body weight during the first week of treatment, when compared to the vehicle. Fasting glycaemia was improved after 4 weeks of treatment with α-GOS, whereas insulin sensitivity (assessed with HOMA-IR) was unaffected at the end of the experiment. Plasma non-esterified fatty acids, low-density lipoprotein (LDL) and total cholesterol were lowered by α-GOS while high-density lipoprotein (HDL) and triglycerides levels remained unaffected. α-GOS markedly improved liver steatosis as well as free fatty acid and triglyceride accumulation in the liver. α-GOS improved plasma lipids and prevented NAFLD development through mechanisms which are independent of body weight management and glycemic control. View Full-Text
Keywords: NAFLD; pre-diabetes; metabolic syndrome; alpha-galacto-oligosaccharides; prebiotic NAFLD; pre-diabetes; metabolic syndrome; alpha-galacto-oligosaccharides; prebiotic

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Chappuis, E.; Morel-Depeisse, F.; Bariohay, B.; Roux, J. Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model. Molecules 2017, 22, 1725.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top